Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Urogenital Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
National Cancer Institute (U.S.) × Clear all
NCT03480152 2020-06-02

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 11 charts
DermatologicGastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡